A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/17/2011	WO2011082331A3 Compositions and methods for treating hepatitis b virus infection
11/17/2011	WO2011082271A3 Substituted triazolo-pyrimidine compounds
11/17/2011	WO2011082270A3 Substituted imidazopyridinyl-aminopyridine compounds
11/17/2011	WO2011081383A3 Composition including naphthoquinone compound for treating and preventing hearing loss
11/17/2011	WO2011079263A3 Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
11/17/2011	WO2011079261A3 Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
11/17/2011	WO2011079133A3 Compounds and methods for kinase modulation, and indications therefor
11/17/2011	WO2011078590A3 Ultraviolet protection composition comprising a blt2 inhibitor
11/17/2011	WO2011077133A3 Method of treatment and screening method
11/17/2011	WO2011076807A3 Lipids, lipid compositions, and methods of using them
11/17/2011	WO2011075665A3 Beta-cell replication promoting compounds and methods of their use
11/17/2011	WO2011074881A3 Substances for inhibiting expression of genes for sensitivity to allergic disorders
11/17/2011	WO2011072290A3 Targeted dendrimer-drug conjugates
11/17/2011	WO2011071968A3 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
11/17/2011	WO2011068941A3 Proline derivatives
11/17/2011	WO2011062955A3 Compounds for modulating tlr2
11/17/2011	WO2011061252A3 Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
11/17/2011	WO2011059505A3 Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
11/17/2011	WO2011038278A3 Micelle encapsulation of therapeutic agents
11/17/2011	WO2011019763A3 Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
11/17/2011	WO2011014850A3 Topical eutectic-based formulations
11/17/2011	WO2011011604A3 Composition and method to alleviate joint pain
11/17/2011	WO2011011077A3 Microbially stable dispersion medium for emulsions
11/17/2011	WO2011008117A3 The use of a sirna oligonucleotide
11/17/2011	WO2011005478A3 Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
11/17/2011	WO2010140007A3 Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
11/17/2011	WO2010137979A8 Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercalcaemia
11/17/2011	WO2010130982A3 Microparticles comprising immunosuppressant
11/17/2011	WO2010034917A3 Monoester of n-undecylenoyl phenylalanine and polyol, method for preparing same, and use of said esters as a skin lightening agent
11/17/2011	WO2010012667A8 Micro-rna mediated modulation of colony stimulating factors
11/17/2011	US20110282485 System with a reservoir for perfusion management
11/17/2011	US20110282464 Reactive Surgical Implants
11/17/2011	US20110281957 Enhanced bioactive formulations of resveratrol
11/17/2011	US20110281956 Use of thymus capitatus extract, satureja hortensis extract, or carvacrol for treating metabolic diseases
11/17/2011	US20110281955 Methods of treating obesity using antioxidant inflammation modulators
11/17/2011	US20110281954 Methods of synthesizing cinacalcet and salts thereof
11/17/2011	US20110281953 Process for preparing and drying solid rasagiline base
11/17/2011	US20110281952 Deuterium-enriched tolterodine
11/17/2011	US20110281951 Compositions and methods for treating amyloidosis
11/17/2011	US20110281950 Compositions and methods for reducing proliferation and viability of lymphoblastoid cells
11/17/2011	US20110281949 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
11/17/2011	US20110281948 Cosmetic and pharmaceutical formulations of calixarene molecules
11/17/2011	US20110281947 Methods of administering diclofenac compositions for treating photodamaged skin
11/17/2011	US20110281946 Polymeric -based composition
11/17/2011	US20110281945 Gastric acid secretion inhibitor, and potassium channel inhibitor
11/17/2011	US20110281944 Method of a rhein compound for inhibiting pancreatic islet beta-cell dysfunction and preventing or treating a pancreatic islet beta-cell dysfunction related disorder
11/17/2011	US20110281942 Tautomycetin and Tautomycetin Analog Biosynthesis
11/17/2011	US20110281941 Combination of lycopene, polyphenol, and vitamins for the care of keratin materials
11/17/2011	US20110281939 Polynucleotide aptamer-based cross-linked materials and uses thereof
11/17/2011	US20110281938 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
11/17/2011	US20110281937 Methods and compositions for treating neuropathic and neurodegenerative conditions
11/17/2011	US20110281936 Methods of treating cognitive disorders by inhibition of gpr12
11/17/2011	US20110281935 Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer
11/17/2011	US20110281934 Micelles of hydrophilically shielded membrane-destabilizing copolymers
11/17/2011	US20110281933 Methods and compositions for the management of cardiovascular disease with oligonucleotides
11/17/2011	US20110281932 Methods to enhance T-cell mediated immune response
11/17/2011	US20110281931 Rna sequence-specific mediators of rna interference
11/17/2011	US20110281929 Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
11/17/2011	US20110281928 Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
11/17/2011	US20110281927 Deuterium-enriched doripenem
11/17/2011	US20110281925 Dual-acting antihypertensive agents
11/17/2011	US20110281923 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
11/17/2011	US20110281922 Amide thiazole derivative, preparation method and uses thereof
11/17/2011	US20110281921 Novel anti-biofilm agents
11/17/2011	US20110281920 Injectable parasiticidal formulations of levamisole and macrocyclic lactones
11/17/2011	US20110281919 Agent for treating or preventing digestive ulcer
11/17/2011	US20110281918 Antifungal Composition
11/17/2011	US20110281917 Substituted Benzimidazoles for the Treatment of Astrocytomas
11/17/2011	US20110281916 Migrastatin analogs and uses thereof
11/17/2011	US20110281914 Fentanyl composition for nasal administration
11/17/2011	US20110281913 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
11/17/2011	US20110281912 Oral dispersible tablet
11/17/2011	US20110281911 Novel forms of eperisone
11/17/2011	US20110281910 Hepatitis C Virus Inhibitors
11/17/2011	US20110281909 Substituted quinoline derivatives as h1 receptor antagonists
11/17/2011	US20110281908 Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
11/17/2011	US20110281907 Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling
11/17/2011	US20110281906 Sustained release formulation for tacrolimus
11/17/2011	US20110281905 Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
11/17/2011	US20110281904 Use of Dextromethorphan in Treating Addictive Behavior or Bipolar Disorder
11/17/2011	US20110281903 Bicyclic heterocyclic spiro compounds
11/17/2011	US20110281902 Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
11/17/2011	US20110281901 Pharmaceutical compositions and methods of making same
11/17/2011	US20110281900 Crystalline Pharmaceutical
11/17/2011	US20110281899 Methods of preventing and treating low bone mass diseases
11/17/2011	US20110281898 Phenoxiacetic acid derivatives
11/17/2011	US20110281897 Heterocyclic compounds and their uses
11/17/2011	US20110281896 Optically pure quinazoline compounds
11/17/2011	US20110281895 Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3ylvinyl)pyrimidine
11/17/2011	US20110281894 Hemifumarate salt
11/17/2011	US20110281893 Compound, synthesis, composition and uses thereof
11/17/2011	US20110281892 Method and formulation for cold treatment in adults and children with increased safety
11/17/2011	US20110281891 N-hydroxyamide derivatives and use thereof
11/17/2011	US20110281890 Piperidine and piperazine derivatives
11/17/2011	US20110281889 5-HT1A Receptor Subtype Agonist
11/17/2011	US20110281888 Fused Bicyclic Kinase Inhibitors
11/17/2011	US20110281887 Compounds and method for treatment of cancer
11/17/2011	US20110281886 Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids
11/17/2011	US20110281885 Therapeutic agents useful for treating pain
11/17/2011	US20110281884 Fused derivatives as pi3kdelta inhibitors

1 ... 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 ... 7860